A detailed history of Derbend Asset Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Derbend Asset Management holds 5,738 shares of ABBV stock, worth $1.03 Million. This represents 0.52% of its overall portfolio holdings.

Number of Shares
5,738
Previous 4,473 28.28%
Holding current value
$1.03 Million
Previous $693,000 50.65%
% of portfolio
0.52%
Previous 0.41%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024

BUY
$159.82 - $182.1 $202,172 - $230,356
1,265 Added 28.28%
5,738 $1.04 Million
Q4 2023

Jan 23, 2024

BUY
$137.6 - $154.97 $17,750 - $19,991
129 Added 2.97%
4,473 $693,000
Q3 2023

Oct 19, 2023

BUY
$133.59 - $154.65 $16,832 - $19,485
126 Added 2.99%
4,344 $647,000
Q2 2023

Jul 20, 2023

BUY
$132.51 - $164.9 $4,107 - $5,111
31 Added 0.74%
4,218 $568,000
Q1 2023

Apr 17, 2023

BUY
$144.61 - $166.54 $4,338 - $4,996
30 Added 0.72%
4,187 $667,000
Q4 2022

Jan 24, 2023

SELL
$138.31 - $165.87 $27,523 - $33,008
-199 Reduced 4.57%
4,157 $0
Q3 2022

Oct 20, 2022

BUY
$134.21 - $153.93 $671 - $769
5 Added 0.11%
4,356 $585,000
Q2 2022

Jul 21, 2022

SELL
$137.62 - $174.96 $613,234 - $779,621
-4,456 Reduced 50.6%
4,351 $666,000
Q4 2021

Feb 02, 2022

SELL
$107.43 - $135.93 $45,657 - $57,770
-425 Reduced 4.6%
8,807 $1.19 Million
Q3 2021

Nov 15, 2021

SELL
$106.4 - $120.78 $85,758 - $97,348
-806 Reduced 8.03%
9,232 $996,000
Q2 2021

Jul 30, 2021

BUY
$105.21 - $117.21 $1.06 Million - $1.18 Million
10,038 New
10,038 $1.13 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Derbend Asset Management Portfolio

Follow Derbend Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Derbend Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Derbend Asset Management with notifications on news.